900642-17-3 Usage
Uses
Used in Pharmaceutical Industry:
Tert-Butyl 4-amino-3-methyl-1-piperidinecarboxylate is used as a key intermediate in the synthesis of various drugs and pharmaceutical products. Its unique molecular structure and reactivity make it an essential component in the development of new medications.
Used in Medicinal Chemistry Research:
Tert-Butyl 4-amino-3-methyl-1-piperidinecarboxylate is used as a building block in medicinal chemistry research. Its potential pharmacological properties allow researchers to explore its applications in the discovery and development of new drugs.
Used in Organic Chemistry:
Tert-Butyl 4-amino-3-methyl-1-piperidinecarboxylate is used as a versatile reagent in organic chemistry. Its unique structure and reactivity enable chemists to synthesize a wide range of organic compounds for various applications.
Check Digit Verification of cas no
The CAS Registry Mumber 900642-17-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,0,0,6,4 and 2 respectively; the second part has 2 digits, 1 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 900642-17:
(8*9)+(7*0)+(6*0)+(5*6)+(4*4)+(3*2)+(2*1)+(1*7)=133
133 % 10 = 3
So 900642-17-3 is a valid CAS Registry Number.
InChI:InChI=1S/C11H22N2O2/c1-8-7-13(6-5-9(8)12)10(14)15-11(2,3)4/h8-9H,5-7,12H2,1-4H3
900642-17-3Relevant academic research and scientific papers
PHENYL AMINO PIPERIDINE mTORC INHIBITORS AND USES THEREOF
-
Paragraph 1339; 1338; 0899; 0897, (2018/05/24)
The present invention provides compounds, compositions thereof, and methods of using the same.
SUBSTITUTED PIPERIDINE COMPOUNDS
-
Paragraph 0309, (2016/06/01)
The present disclosure provides substituted piperidine compounds having Formula (I), and the pharmaceutically acceptable salts and solvates thereof, wherein R1, B, X, and Z are defined as set forth in the specification. The present disclosure i
NOVEL HETEROCYCLIC CARBOXAMIDES AS M1 AGONISTS
-
Page/Page column 75, (2009/10/21)
The present invention relates to novel M1 agonistic compounds of formula (I) and their use in the treatment of cognitive impairment associated i.a. with schizophrenia and in the treatment of other diseases mediated by the muscarinic M1 receptor.
